# Denali Therapeutics Inc.: filings

DNLI · Nasdaq · CIK 1714899 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dnli.md) · [Financials](/companies/dnli/financials.md) · [Filings](/companies/dnli/filings.md) · [Insiders](/companies/dnli/insiders.md)

## Reports and events: 150 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 397, 8-K 99, 144 78, SC 13G/A 36, 10-Q 26, 3 24, SC 13G 13, 4/A 11, 10-K 9, DEF 14A 9, DEFA14A 9, S-8 9, SCHEDULE 13G/A 8, CORRESP 7, 424B5 6, UPLOAD 6, CT ORDER 5, ARS 4, S-3ASR 4, 3/A 2, 8-K/A 2, DRS/A 2, S-1/A 2, 10-K/A 1, 10-Q/A 1, 424B4 1, 5 1, 8-A12B 1, CERTNAS 1, D 1, DRS 1, DRSLTR 1, EFFECT 1, S-1 1, SCHEDULE 13G 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:08 ET | [10-Q](/filings/0001714899-26-000097.md) | Quarterly report, period 2026-06-30 | 0001714899-26-000097 |
| 2026-08-06 | 16:03 ET | [8-K](/filings/0001714899-26-000096.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-26-000096 |
| 2026-07-28 | 21:01 ET | [8-K](/filings/0001714899-26-000086.md) | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001714899-26-000086 |
| 2026-06-18 | 08:01 ET | [8-K](/filings/0001714899-26-000081.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-26-000081 |
| 2026-06-04 | 18:43 ET | [8-K](/filings/0001714899-26-000074.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-26-000074 |
| 2026-05-22 | 18:17 ET | [8-K](/filings/0001714899-26-000070.md) | 7.01 Regulation FD disclosure | 0001714899-26-000070 |
| 2026-05-07 | 16:12 ET | [10-Q](/filings/0001714899-26-000064.md) | Quarterly report, period 2026-03-31 | 0001714899-26-000064 |
| 2026-05-07 | 16:03 ET | [8-K](/filings/0001714899-26-000062.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-26-000062 |
| 2026-04-21 | 16:31 ET | [DEF 14A](/filings/0001714899-26-000054.md) | Proxy statement, period 2025-12-31 | 0001714899-26-000054 |
| 2026-04-03 | 14:43 ET | [8-K](/filings/0001714899-26-000042.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001714899-26-000042 |
| 2026-03-31 | 08:30 ET | [8-K](/filings/0001714899-26-000036.md) | 2.03 New direct financial obligation; 7.01 Regulation FD disclosure | 0001714899-26-000036 |
| 2026-03-25 | 15:13 ET | [8-K](/filings/0001714899-26-000030.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-26-000030 |
| 2026-02-26 | 16:11 ET | [10-K](/filings/0001714899-26-000021.md) | Annual report, period 2025-12-31 | 0001714899-26-000021 |
| 2026-02-26 | 16:07 ET | [8-K](/filings/0001714899-26-000020.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-26-000020 |
| 2026-01-06 | 08:02 ET | [8-K](/filings/0001714899-26-000004.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-26-000004 |
| 2025-12-10 | 17:21 ET | [8-K](/filings/0001628280-25-056363.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-25-056363 |
| 2025-12-04 | 07:01 ET | [8-K](/filings/0001714899-25-000209.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001714899-25-000209 |
| 2025-12-04 | 07:01 ET | [8-K](/filings/0001714899-25-000208.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001714899-25-000208 |
| 2025-11-06 | 16:05 ET | [10-Q](/filings/0001714899-25-000193.md) | Quarterly report, period 2025-09-30 | 0001714899-25-000193 |
| 2025-11-06 | 16:03 ET | [8-K](/filings/0001714899-25-000192.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-25-000192 |
| 2025-10-14 | 08:10 ET | [8-K](/filings/0001714899-25-000180.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000180 |
| 2025-08-11 | 16:25 ET | [10-Q](/filings/0001714899-25-000170.md) | Quarterly report, period 2025-06-30 | 0001714899-25-000170 |
| 2025-08-11 | 16:03 ET | [8-K](/filings/0001714899-25-000167.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-25-000167 |
| 2025-07-07 | 08:04 ET | [8-K](/filings/0001714899-25-000146.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000146 |
| 2025-06-03 | 16:05 ET | [8-K](/filings/0001714899-25-000128.md) | 1.01 Entry into a material agreement; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-25-000128 |
| 2025-05-06 | 16:04 ET | [10-Q](/filings/0001714899-25-000105.md) | Quarterly report, period 2025-03-31 | 0001714899-25-000105 |
| 2025-05-06 | 16:03 ET | [8-K](/filings/0001714899-25-000104.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-25-000104 |
| 2025-04-17 | 16:05 ET | [DEF 14A](/filings/0001714899-25-000087.md) | Proxy statement, period 2024-12-31 | 0001714899-25-000087 |
| 2025-04-02 | 08:02 ET | [8-K](/filings/0001714899-25-000077.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000077 |
| 2025-03-05 | 17:26 ET | [8-K](/filings/0001714899-25-000072.md) | 7.01 Regulation FD disclosure | 0001714899-25-000072 |
| 2025-02-27 | 16:12 ET | [8-K](/filings/0001714899-25-000067.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-25-000067 |
| 2025-02-27 | 16:05 ET | [10-K](/filings/0001714899-25-000066.md) | Annual report, period 2024-12-31 | 0001714899-25-000066 |
| 2025-01-13 | 08:03 ET | [8-K](/filings/0001714899-25-000054.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000054 |
| 2025-01-07 | 18:13 ET | [8-K](/filings/0001714899-25-000007.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-25-000007 |
| 2024-11-18 | 16:02 ET | [8-K](/filings/0001714899-24-000233.md) | 5.03 Amendment to articles or bylaws | 0001714899-24-000233 |
| 2024-11-06 | 16:17 ET | [10-Q](/filings/0001714899-24-000216.md) | Quarterly report, period 2024-09-30 | 0001714899-24-000216 |
| 2024-11-06 | 16:16 ET | [8-K](/filings/0001714899-24-000215.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-24-000215 |
| 2024-10-10 | 16:02 ET | [8-K](/filings/0001714899-24-000205.md) | 7.01 Regulation FD disclosure | 0001714899-24-000205 |
| 2024-08-01 | 06:52 ET | [10-Q](/filings/0001714899-24-000169.md) | Quarterly report, period 2024-06-30 | 0001714899-24-000169 |
| 2024-08-01 | 06:48 ET | [8-K](/filings/0001714899-24-000168.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-24-000168 |
| 2024-05-31 | 16:01 ET | [8-K](/filings/0001714899-24-000125.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001714899-24-000125 |
| 2024-05-07 | 16:05 ET | [10-Q](/filings/0001714899-24-000121.md) | Quarterly report, period 2024-03-31 | 0001714899-24-000121 |
| 2024-05-07 | 16:03 ET | [8-K](/filings/0001714899-24-000120.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-24-000120 |
| 2024-04-18 | 16:03 ET | [DEF 14A](/filings/0001714899-24-000110.md) | Proxy statement, period 2023-12-31 | 0001714899-24-000110 |
| 2024-02-28 | 20:16 ET | [10-K](/filings/0001714899-24-000086.md) | Annual report, period 2023-12-31 | 0001714899-24-000086 |
| 2024-02-27 | 08:07 ET | [8-K](/filings/0001714899-24-000076.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001714899-24-000076 |
| 2024-02-27 | 08:03 ET | [8-K](/filings/0001714899-24-000075.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-24-000075 |
| 2024-02-16 | 08:02 ET | [8-K](/filings/0001714899-24-000065.md) | 7.01 Regulation FD disclosure | 0001714899-24-000065 |
| 2024-01-08 | 08:06 ET | [8-K](/filings/0001714899-24-000031.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001714899-24-000031 |
| 2023-11-07 | 16:05 ET | [10-Q](/filings/0001714899-23-000146.md) | Quarterly report, period 2023-09-30 | 0001714899-23-000146 |

Page 1 of 3. [Older](/companies/dnli/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.